Primary Myelofibrosis
The World Health Organization (WHO) classification of myeloproliferative neoplasms (MPN)[1,2] was revised in 2008 and defines the diagnosis of Primary Myelofibrosis (PMF) according to the following algorithm:
A patient must meet all 3 major criteria and 2 minor criteria:
Major Criteria:
- Megakaryocyte proliferation and atypia
- Atypia: small to large megakaryocytes with an aberrant nuclear/cytoplasmic ratio and hyperchromatic and irregularly folded nuclei and dense clusteringaccompanied by one of the following:
- reticulin and / or collagen fibrosis
- in the absence of reticulin fibrosis, the megakaryocyte changes must be accompanied by increased bone marrow cellularity, granulocytic proliferation and often decreased erythropoiesis (i.e. prefibrotic PMF).
- Not meeting WHO criteria for CML, PV, MDS, or other myeloid neoplasm
- One of the following
- Demonstration of the JAK2 V617F mutation
- Demonstration of a other clonal marker
- No evidence of reactive bone marrow fibrosis
- Atypia: small to large megakaryocytes with an aberrant nuclear/cytoplasmic ratio and hyperchromatic and irregularly folded nuclei and dense clusteringaccompanied by one of the following:
Minor Criteria:
- Leukoerythroblastosis
- Increased Serum LDH
- Anemia
- Palpable Splenomegaly
References
- Swerdlow S, Campo E, Harris N. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IRAC Press. 2008:Lyon, France.
- Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009;115(17):3842-3847
- Visit also the FIM (French Intergroup MPD) website.